Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

AstraZeneca is a company with a turbulent history but ... especially in research and development and geographical presence. I am convinced that we will see considerable growth in the years ...

Presentation Operator Good morning, and welcome to the Interpublic Group 4th-Quarter and Full-Year 2024 Conference Call. All ...

Randomised 1:1 to receive either the placebo of lecanemab 10mg/kg IV biweekly, stratification was according to clinical subgroup (MCI due to AD or mild AD), as well as presence or absence of ...

However, the company's... Strategic growth investment ... and entertainment venues engage with their audience Expanded geographic presence and new LATAM leader will bring proven digital signage ...

As the company has a robust geographic presence and is focused on expansion ... segment and the growth of the new therapies business. Merck is one of the leaders in single-use assemblies in ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. The Dow is a highly recognized and influential stock market index that ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...